

产品名称: **Thiamet G**

产品别名: **Thiamet G0nDiscontinued; Thiamet G; Thiamet G;**

生物活性:																						
<b>Description</b>	Thiamet G is a potent and selective inhibitor of O-GlcNAcase (OGA), which acts to remove O-GlcNAc from modified proteins, with $K_i$ of 20 nM for human OGA.																					
<b>IC<sub>50</sub> &amp; Target</b>	Ki: 20 nM (Human OGA)[1]																					
<b>In Vitro</b>	Thiamet G (1 $\mu$ M) induces a clear increase in the accumulation of O-GlcNAcylated proteins of ATDC5 cells. O-GlcNAc accumulation induced by Thiamet G also evokes a clear increase in the activity of these MMPs. Thiamet G (1 $\mu$ M) induces the phosphorylation of JNK, ERK, and p38 but not phosphorylation of Akt[2]. Thiamet G (0.1-10 $\mu$ M) does not significantly affect the cell viability. Thiamet G decreases phosphorylation of tau and alters the microtubule dynamics[3].																					
<b>In Vivo</b>	Thiamet G (500 mg/kg/d) increases global and tau O-GlcNAc and reduces neurodegeneration. Thiamet G-treated group has 1.4-fold more motor neurons and hinders tau-driven neurodegeneration within this transgenic model. Thiamet G treatment therefore has no detectable effect on mice lacking the P301L transgene, indicating that prevention of neurodegeneration and weight loss is mediated by Thiamet G treatment only in the context of the P301L transgene. In Thiamet G-treated mice, the O-GlcNAc increases in the brain and spinal cord tissues[1]. Thiamet G (20 mg/kg, i.p.) increases O-GlcNAc levels in brain, liver, and knee of the C57BL/6 mice in a dose-dependent manner[2].																					
<b>Solvent&amp;Solubility</b>	<p><b>In Vitro:</b></p> <p>H<sub>2</sub>O : <math>\geq</math> 50 mg/mL (201.37 mM)</p> <p>DMSO : <math>\geq</math> 45 mg/mL (181.23 mM)</p> <p>* "<math>\geq</math>" means soluble, but saturation unknown.</p>																					
	<table border="1"> <thead> <tr> <th rowspan="2">Preparing Stock Solutions</th> <th>Solvent Mass</th> <th rowspan="2">1 mg</th> <th rowspan="2">5 mg</th> <th rowspan="2">10 mg</th> </tr> <tr> <th>Concentration</th> </tr> </thead> <tbody> <tr> <td></td> <td>1 mM</td> <td>4.0274 mL</td> <td>20.1369 mL</td> <td>40.2739 mL</td> </tr> <tr> <td></td> <td>5 mM</td> <td>0.8055 mL</td> <td>4.0274 mL</td> <td>8.0548 mL</td> </tr> <tr> <td></td> <td>10 mM</td> <td>0.4027 mL</td> <td>2.0137 mL</td> <td>4.0274 mL</td> </tr> </tbody> </table>	Preparing Stock Solutions	Solvent Mass	1 mg	5 mg	10 mg	Concentration		1 mM	4.0274 mL	20.1369 mL	40.2739 mL		5 mM	0.8055 mL	4.0274 mL	8.0548 mL		10 mM	0.4027 mL	2.0137 mL	4.0274 mL
	Preparing Stock Solutions		Solvent Mass				1 mg	5 mg	10 mg													
		Concentration																				
	1 mM	4.0274 mL	20.1369 mL	40.2739 mL																		
	5 mM	0.8055 mL	4.0274 mL	8.0548 mL																		
	10 mM	0.4027 mL	2.0137 mL	4.0274 mL																		
<p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液, 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。</p>																						
<b>References</b>	<p>[1]. Yuzwa SA, et al. <u>Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation.</u> Nat Chem Biol. 2012 Feb 26;8(4):393-9.</p> <p>[2]. Andrés-Bergós J, et al. <u>The increase in O-linked N-acetylglucosamine protein modification stimulates chondrogenic differentiation both in vitro and in vivo.</u> J Biol Chem. 2012 Sep 28;287(40):33615-28.</p> <p>[3]. Ding N, et al. <u>Thiamet-G-mediated inhibition of O-GlcNAcase sensitizes human leukemia cells to microtubule-stabilizing agent paclitaxel.</u> Biochem Biophys Res Commun. 2014 Oct 24;453(3):392-7.</p>																					
实验参考:																						
<b>Cell Assay</b>	Jurkat cells are seeded at 6000 cells/well in a 96-well plate, and 12 h later, cells are treated with compounds for the indicated time. Cell viability is determined by XTT assay. [3]																					
	For the Thiamet G dose dependence study, six 23-day-old male C57BL/6 mice receive single intraperitoneal injections of either 0, 10, 20, 100, 200, or 500 mg/kg of Thiamet G dissolved in																					

<b>Animal Administration</b>	phosphate-buffered saline (PBS) and then are euthanized 8 h later to evaluate the O-GlcNAc levels in different tissues (brain, liver, muscle, and knee). The time of sacrifice is chosen on the basis of previously published data on Thiamet G in rodents, which demonstrates that the peak level of O-GlcNAc proteins following administration of the drug is achieved after 8-10 h. Tissues are collected immediately after sacrifice, flash-frozen in liquid nitrogen, and stored at $-80^{\circ}\text{C}$ until required for use. [2]
<b>Kinase Assay</b>	All enzymatic assays are performed in triplicate at $37^{\circ}\text{C}$ using 4-methylumbelliferyl N-acetyl- $\beta$ -d-glucosaminide dehydrate as substrate. 1 nM of purified OGA is incubated with the compounds for 5 min, and then 0.2 mM of the substrate is added. The liberation of 4-methylumbellifery is monitored by kinetic reading at excitation/emission 355/460 nm using a Tecan M200 plate in a mode of 60 s/cycle and 15 cycles in total. [3]
<b>References</b>	<p>[1]. <a href="#">Yuzwa SA, et al. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol. 2012 Feb 26;8(4):393-9.</a></p> <p>[2]. <a href="#">Andrés-Bergós J, et al. The increase in O-linked N-acetylglucosamine protein modification stimulates chondrogenic differentiation both in vitro and in vivo. J Biol Chem. 2012 Sep 28;287(40):33615-28.</a></p> <p>[3]. <a href="#">Ding N, et al. Thiamet-G-mediated inhibition of O-GlcNAcase sensitizes human leukemia cells to microtubule-stabilizing agent paclitaxel. Biochem Biophys Res Commun. 2014 Oct 24;453(3):392-7.</a></p>



源叶生物